Abstract | BACKGROUND: CASE PRESENTATION: A 77-year-old man was referred to our hospital because of nausea and vomiting. Computed tomography and upper gastrointestinal endoscopy revealed a type 1 tumor arising from the gastric antrum and extending into the duodenal bulb. He underwent distal gastrectomy (D2) with Roux-en-Y reconstruction. Histopathologically, the tumor had mixed adenocarcinoma and sarcoma components. According to the tumor-node- metastasis classification, the diagnosis was primary gastric carcinosarcoma pT1bN1M0 stage IB. Liver metastasis was detected 2 months after surgery; multiple lung metastases were detected 17 month after surgery. A genomic profiling test was performed using liver specimens as the patient became refractory to chemotherapy commonly used for gastric cancer, and the test revealed FGFR2 amplification along with TP53 R209*, AKT3 N127D, NOTCH1 A2036T, and POLD1 M161I. The patient was treated with pazopanib (800 mg/daily), and the tumor growth was controlled for 11 months. CONCLUSIONS:
|
Authors | Hirokatsu Hayashi, Akitaka Makiyama, Naoki Okumura, Itaru Yasufuku, Chiemi Saigo, Tamotsu Takeuchi, Tatsuhiko Miyazaki, Yoshihiro Tanaka, Nobuhisa Matsuhashi, Katsutoshi Murase, Takao Takahashi, Manabu Futamura, Kazuhiro Yoshida |
Journal | BMC gastroenterology
(BMC Gastroenterol)
Vol. 22
Issue 1
Pg. 360
(Jul 28 2022)
ISSN: 1471-230X [Electronic] England |
PMID | 35902814
(Publication Type: Case Reports, Journal Article, Review)
|
Copyright | © 2022. The Author(s). |
Chemical References |
- Indazoles
- Pyrimidines
- Sulfonamides
- pazopanib
- FGFR2 protein, human
- Receptor, Fibroblast Growth Factor, Type 2
|
Topics |
- Aged
- Carcinosarcoma
(drug therapy, genetics, pathology)
- Gastrectomy
(methods)
- Humans
- Indazoles
(therapeutic use)
- Male
- Pyrimidines
- Receptor, Fibroblast Growth Factor, Type 2
(genetics, therapeutic use)
- Stomach Neoplasms
(drug therapy, genetics, pathology)
- Sulfonamides
|